159 related articles for article (PubMed ID: 31537471)
1. Long-term administration of pegylated liposomal doxorubicin at almost twice the recommended lifetime dose in 10 years without cardiotoxicity in a Japanese patient with HIV-associated Kaposi sarcoma.
Yokota K; Yotsumoto M; Muramatsu T; Saito M; Kamikubo Y; Ichiki A; Chikasawa Y; Bingo M; Hagiwara T; Amano K; Fukutake K
J Infect Chemother; 2020 Feb; 26(2):289-291. PubMed ID: 31537471
[TBL] [Abstract][Full Text] [Related]
2. Histological evidence for the cardiac safety of high-dose pegylated liposomal doxorubicin in a patient with HIV-associated Kaposi sarcoma: a case report and literature review.
Ishihara A; Hatakeyama S; Suzuki J; Amano Y; Sasahara T; Toshima M; Morisawa Y
BMC Infect Dis; 2019 Oct; 19(1):848. PubMed ID: 31615436
[TBL] [Abstract][Full Text] [Related]
3. Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value.
Skubitz KM; Blaes AH; Konety SH; Francis GS
Cancer Chemother Pharmacol; 2017 Oct; 80(4):787-798. PubMed ID: 28856562
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of an HIV-positive patient with unmasking Kaposi's sarcoma immune reconstitution inflammatory syndrome.
Speicher DJ; Sehu MM; Johnson NW; Shaw DR
J Clin Virol; 2013 Jul; 57(3):282-5. PubMed ID: 23578530
[TBL] [Abstract][Full Text] [Related]
5. Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin.
Martín-Carbonero L; Palacios R; Valencia E; Saballs P; Sirera G; Santos I; Baldobí F; Alegre M; Goyenechea A; Pedreira J; González del Castillo J; Martínez-Lacasa J; Ocampo A; Alsina M; Santos J; Podzamczer D; González-Lahoz J;
Clin Infect Dis; 2008 Aug; 47(3):410-7. PubMed ID: 18582203
[TBL] [Abstract][Full Text] [Related]
6. Pegylated liposomal doxorubicin as first line treatment in aids-related Kaposi's sarcoma: a real-life study.
Dalu D; Fasola C; Ammoni L; De Francesco D; Cona MS; Rota S; Ferrario S; Gambaro A; Tosca N; Piva S; La Verde N
J Chemother; 2021 Sep; 33(5):342-347. PubMed ID: 34060438
[TBL] [Abstract][Full Text] [Related]
7. Therapy of special HIV-associated diseases: HCV-HIV-co-infection and AIDS-related Kaposi's sarcoma - official satellite to the 7th European Conference on Clinical Aspects and Treatment of HIV-infection, October 23, 1999 in Lisbon, Portugal.
Goebel FD; Jablonowski H
Eur J Med Res; 1999 Dec; 4(12):507-13. PubMed ID: 10611054
[TBL] [Abstract][Full Text] [Related]
8. Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma.
Martin-Carbonero L; Barrios A; Saballs P; Sirera G; Santos J; Palacios R; Valencia ME; Alegre M; Podzamczer D; González-Lahoz J;
AIDS; 2004 Aug; 18(12):1737-40. PubMed ID: 15280789
[TBL] [Abstract][Full Text] [Related]
9. Low to moderate cumulative doses of pegylated liposomal doxorubicin in the treatment of classic Kaposi sarcoma in elderly patients with comorbidities.
Potouridou I; Korfitis C; Ioannidou D; Polydorou D; Zakopoulou N; Stratigos AJ; Katsambas AD
Br J Dermatol; 2008 Feb; 158(2):431-2. PubMed ID: 18067475
[No Abstract] [Full Text] [Related]
10. Absence of cardiotoxicity with prolonged treatment and large accumulating doses of pegylated liposomal doxorubicin.
Blank N; Laskov I; Kessous R; Kogan L; Lau S; Sebag IA; Gotlieb WH; Rudski L
Cancer Chemother Pharmacol; 2017 Oct; 80(4):737-743. PubMed ID: 28801766
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy.
Cianfrocca M; Lee S; Von Roenn J; Tulpule A; Dezube BJ; Aboulafia DM; Ambinder RF; Lee JY; Krown SE; Sparano JA
Cancer; 2010 Aug; 116(16):3969-77. PubMed ID: 20564162
[TBL] [Abstract][Full Text] [Related]
12. Treatment of HIV-1-associated Kaposi's sarcoma with pegylated liposomal doxorubicin and HAART simultaneously induces effective tumor remission and CD4+ T cell recovery.
Lichterfeld M; Qurishi N; Hoffmann C; Hochdorfer B; Brockmeyer NH; Arasteh K; Mauss S; Rockstroh JK;
Infection; 2005 Jun; 33(3):140-7. PubMed ID: 15940415
[TBL] [Abstract][Full Text] [Related]
13. Liposomal pegylated doxorubicin versus low-dose recombinant interferon Alfa-2a in the treatment of advanced classic Kaposi's sarcoma; retrospective analysis of three German centers.
Kreuter A; Rasokat H; Klouche M; Esser S; Bader A; Gambichler T; Altmeyer P; Brockmeyer NH
Cancer Invest; 2005; 23(8):653-9. PubMed ID: 16377582
[TBL] [Abstract][Full Text] [Related]
14. A Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab followed by Bevacizumab Monotherapy in Patients with Advanced Kaposi Sarcoma.
Ramaswami R; Uldrick TS; Polizzotto MN; Wyvill KM; Goncalves P; Widell A; Lurain K; Steinberg SM; Figg WD; Tosato G; Whitby D; Yarchoan R
Clin Cancer Res; 2019 Jul; 25(14):4238-4247. PubMed ID: 30979736
[TBL] [Abstract][Full Text] [Related]
15. Selective cardiac surveillance in patients with gynecologic cancer undergoing treatment with pegylated liposomal doxorubicin (PLD).
Kushnir CL; Angarita AM; Havrilesky LJ; Thompson S; Spahlinger D; Sinno AK; Tanner EJ; Secord AA; Roche KL; Stone RL; Fader AN
Gynecol Oncol; 2015 Jun; 137(3):503-7. PubMed ID: 25735254
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy.
Northfelt DW; Dezube BJ; Thommes JA; Levine R; Von Roenn JH; Dosik GM; Rios A; Krown SE; DuMond C; Mamelok RD
J Clin Oncol; 1997 Feb; 15(2):653-9. PubMed ID: 9053490
[TBL] [Abstract][Full Text] [Related]
17. Necrotizing leg gangrene from invasive cutaneous Kaposi sarcoma, reversed by pegylated liposomal doxorubicin.
Goff CB; Stapleton A; Aboulafia DM; Dasanu CA
J Oncol Pharm Pract; 2022 Jun; 28(4):1003-1008. PubMed ID: 35037777
[TBL] [Abstract][Full Text] [Related]
18. Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study.
Jehn CF; Hemmati P; Lehenbauer-Dehm S; Kümmel S; Flath B; Schmid P
Clin Breast Cancer; 2016 Dec; 16(6):514-519. PubMed ID: 27395417
[TBL] [Abstract][Full Text] [Related]
19. Multiple remissions of extracavitary primary effusion lymphoma treated with a single cycle of liposomal doxorubicin in a patient infected with HIV.
Chen J; Mehraj V; Szabo J; Routy B; Michel RP; Routy JP
Curr Oncol; 2018 Dec; 25(6):e592-e596. PubMed ID: 30607128
[TBL] [Abstract][Full Text] [Related]
20. Pegylated liposomal doxorubicin-induced renal toxicity in retroperitoneal liposarcoma: a case report and literature review.
Savani M; Woerner K; Bu L; Birkenbach M; Skubitz KM
Cancer Chemother Pharmacol; 2021 Feb; 87(2):289-294. PubMed ID: 33388949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
